EZH2 as a new therapeutic target in brain tumors: molecular landscape, therapeutic targeting and future prospects

Paskeh, Mahshid Deldar Abad and Mehrabi, Atefeh and Gholami, Mohammad Hossein and Zabolian, Amirhossein and Ranjbar, Ehsan and Saleki, Hossein and Ranjbar, Adnan and Hashemi, Mehrdad and Ertas, Yavuz Nuri and Hushmandi, Kiavash and Mirzaei, Sepideh and Ashrafizadeh, Milad and Zarrabi, Ali and Samarghandian, Saeed (2022) EZH2 as a new therapeutic target in brain tumors: molecular landscape, therapeutic targeting and future prospects. Biomedicine and Pharmacotherapy, 146 . ISSN 0753-3322 (Print) 1950-6007 (Online)

Full text not available from this repository. (Request a copy)


Brain tumors are responsible for high mortality and morbidity worldwide. The brain tumor treatment depends on identification of molecular pathways involved in progression and malignancy. Enhancer of zeste homolog 2 (EZH2) has obtained much attention in recent years in field of cancer therapy due to its aberrant expression and capacity in modulating expression of genes by binding to their promoter and affecting methylation status. The present review focuses on EZH2 signaling in brain tumors including glioma, glioblastoma, astrocytoma, ependymomas, medulloblastoma and brain rhabdoid tumors. EZH2 signaling mainly participates in increasing proliferation and invasion of cancer cells. However, in medulloblastoma, EZH2 demonstrates tumor-suppressor activity. Furthermore, EZH2 can regulate response of brain tumors to chemotherapy and radiotherapy. Various molecular pathways can function as upstream mediators of EZH2 in brain tumors including lncRNAs and miRNAs. Owing to its enzymatic activity, EZH2 can bind to promoter of target genes to induce methylation and affects their expression. EZH2 can be considered as an independent prognostic factor in brain tumors that its upregulation provides undesirable prognosis. Both anti-tumor agents and gene therapies such as siRNA have been developed for targeting EZH2 in cancer therapy.
Item Type: Article
Uncontrolled Keywords: Biomarker; Drug resistance; Enhancer of zeste homolog 2 (EZH2); EZH2 inhibitors; Non-coding RNAs
Divisions: Faculty of Engineering and Natural Sciences
Sabancı University Nanotechnology Research and Application Center
Depositing User: Milad Ashrafizadeh
Date Deposited: 26 Aug 2022 23:57
Last Modified: 26 Aug 2022 23:57
URI: https://research.sabanciuniv.edu/id/eprint/43900

Actions (login required)

View Item
View Item